{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:53:44Z","timestamp":1791244424403,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01195-y","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:02:30Z","timestamp":1791208950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The divergence in new therapy options for patients undergoing bladder-sparing radiation versus cystectomy"],"prefix":"10.1038","author":[{"given":"Mohini","family":"Varughese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-584X","authenticated-orcid":false,"given":"Anna","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"1195_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bju.15970","volume":"131","author":"JWF Catto","year":"2023","unstructured":"Catto, J. W. F. et al. Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU Int. 131, 734\u2013744 (2023).","journal-title":"BJU Int."},{"key":"1195_CR2","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.lanepe.2025.101385","volume":"56","author":"MP Coleman","year":"2025","unstructured":"Coleman, M. P. et al. Trends over 48 years in a one-number index of survival for all cancers combined, England and Wales (1971-2018): a population-based registry study. Lancet Reg. Health Eur. 56, 101385 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1195_CR3","unstructured":"National statistics, Accredited official statistics. Cancer Survival in England, cancers diagnosed 2016 to 2020, followed up to 2021. NHS https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-survival-in-england\/cancers-diagnosed-2016-to-2020-followed-up-to-2021 (2023)."},{"key":"1195_CR4","volume":"3","author":"MD Shelley","year":"2001","unstructured":"Shelley, M. D., Barber, J. & Mason, M. D. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst. Rev. 3, CD002079 (2001).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1195_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bju.13900","volume":"120","author":"RA Huddart","year":"2017","unstructured":"Huddart, R. A. et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 120, 639\u2013650 (2017).","journal-title":"BJU Int."},{"key":"1195_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 24, 669\u2013681 (2023).","journal-title":"Lancet Oncol."},{"key":"1195_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"1195_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","volume":"87","author":"R Huddart","year":"2025","unstructured":"Huddart, R. et al. Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial. Eur. Urol. 87, 60\u201370 (2025).","journal-title":"Eur. Urol."},{"key":"1195_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta, S. et al. Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur. Urol. 89, 18\u201328 (2026).","journal-title":"Eur. Urol."},{"key":"1195_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.euf.2020.01.013","volume":"7","author":"JB John","year":"2021","unstructured":"John, J. B. et al. Treatment allocation and survival in patients diagnosed with nonmetastatic muscle-invasive bladder cancer: an analysis of a national patient cohort in England. Eur. Urol. Focus 7, 359\u2013365 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"1195_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. 394, 1257\u20131269 (2026).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 16","key":"1195_CR13","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/JCO.2026.44.16_suppl.4504","volume":"44","author":"ND James","year":"2026","unstructured":"James, N. D. et al. Feasibility and safety results from RAD-IO: a multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 44\u00a0(Suppl. 16), 4504 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1195_CR14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41591-026-04271-3","volume":"32","author":"J-JJ Mellema","year":"2026","unstructured":"Mellema, J.-J. J. et al. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 32, 1241\u20131248 (2026).","journal-title":"Nat. Med."},{"key":"1195_CR15","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1200\/JCO-25-01608","volume":"43","author":"A Necchi","year":"2025","unstructured":"Necchi, A. et al. End points for the next-generation bladder-sparing perioperative trials for patients with muscle-invasive bladder cancer. J. Clin. Oncol. 43, 3536\u20133544 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01195-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01195-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01195-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:34Z","timestamp":1791241654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01195-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":15,"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01195-y","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"5 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}